Cell Reports (Nov 2023)

A bacteria-derived tetramerized protein ameliorates nonalcoholic steatohepatitis in mice via binding and relocating acetyl-coA carboxylase

  • Yan Lin,
  • Mingkun Yang,
  • Li Huang,
  • Fan Yang,
  • Jiachen Fan,
  • Yulong Qiang,
  • Yuting Chang,
  • Wenjie Zhou,
  • Leilei Yan,
  • Jie Xiong,
  • Jie Ping,
  • Shizhen Chen,
  • Dong Men,
  • Feng Li

Journal volume & issue
Vol. 42, no. 11
p. 113453

Abstract

Read online

Summary: Increased de novo lipogenesis (DNL) is a major feature of nonalcoholic steatohepatitis (NASH). None of the drugs targeting the catalytic activity of acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in the DNL process, have been approved by the FDA. Whether cytosolic ACC1 can be regulated spatially remains to be explored. Herein, we find that streptavidin (SA), which is a bacterium-derived tetrameric protein, forms cytosolic condensates and efficiently induces a spatial re-localization of ACC1 in liver cells, concomitant with inhibited lipid accumulation. Both SA tetrameric structure and multivalent protein interaction are required for condensate formation. Interestingly, the condensates are further characterized as gel-like membraneless organelle (SAGMO) and significantly restrict the cytosolic dispersion of ACC1 and fatty acid synthase. Notably, AAV-mediated delivery of SA partially blocks mouse liver DNL and ameliorates NASH without eliciting hypertriglyceridemia. In summary, our study shows that insulating lipogenesis-related proteins by SAGMO might be effective for NASH treatment.

Keywords